ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics
Provided By PR Newswire
Last update: Oct 24, 2025
SAN DIEGO, Oct. 24, 2025 /PRNewswire/ -- ChemDiv, a global provider of integrated drug discovery solutions, today announced that it will continue providing chemistry, computational, and clinical pharmacology support to Clywedog Therapeutics as the company enters into a definitive merger agreement with Barinthus Therapeutics (NASDAQ: BRNS). The combined entity will operate under the name Clywedog Therapeutics, Inc. and is expected to list on Nasdaq under the ticker CLYD upon closing. The merged portfolio will focus on advancing clinical-stage candidates in Type 1 diabetes (T1D), Type 2 diabetes (T2D), and celiac disease.
Read more at prnewswire.com
